Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AstraZeneca Files COVID Antibody in Japan, Seeks Special Approval
June 9, 2022
- All FAD Agents in Japan to Be Discontinued as Kyowa Hakko Bio Quits API Production
June 9, 2022
- Gilead Japan Flaunts Unique Pipeline Candidates for HIV, COVID, Oncology
June 9, 2022
- Lilly/Daiichi Sankyo’s Migraine Med Reyvow Hits Japan Market
June 9, 2022
- Eisai Ups Earnings Guidance for FY2022
June 9, 2022
- Idorsia Japan Set to File Its 2nd and 3rd Drugs Early Next Year, Eyes 80 Billion Yen Sales in 5 Years
June 9, 2022
- Horizon Taps Yoshihide Okino as VP and Japan GM
June 8, 2022
- Novartis Sees CML Med Scemblix as Growth Driver over Next Decade, 1st Line Use Holds Key
June 8, 2022
- Japan Ethical Drug Sales Slip 1.9% in April: Crecon
June 8, 2022
- Daiichi Sankyo’s HER3-Directed ADC Shows Promise in Breast Cancer
June 7, 2022
- Enhertu Delivers Stellar PIII Data in HER2 Low Breast Cancer
June 7, 2022
- Kissei Launches MPA/GPA Med Tavneos in Japan
June 7, 2022
- Opdivo Grabs Japan Sales Crown for 5 Months Running in May: Encise
June 7, 2022
- FoundationOne Gets Nod as CDx for 4 Drugs: Chugai
June 6, 2022
- FDA to Review Myfembree for Long-Term Use in Uterine Fibroids
June 6, 2022
- Sanofi’s Sakigake-Tagged ASMD Drug Hits Japan Market
June 6, 2022
- Chugai Eyes Continuous Production of Investigational Biologics by Late 2020s: Executive
June 6, 2022
- Keytruda Most Promoted Drug via In-Hospital Seminars for 1st Time in April: Intage
June 6, 2022
- Bayer Rolls Out CKD Drug Kerendia in Japan
June 3, 2022
- Gilead Japan Eyes High-Single-Digit Annual Growth with Oncology as Third Biz Pillar
June 3, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…